Based on NCCN guidelines for Spindle Cell Sarcoma, what tests or steps might I be missing

Understanding Marlo's Testing Plan Against NCCN Sarcoma Guidelines

Based on the documents you've shared and NCCN Guidelines for Soft Tissue Sarcoma, let me help you understand what's been done and what gaps might exist.

What Your Documents Show Has Been Completed

From Marlo's records, I can see you've already pursued:

✅ Pathology & Diagnosis

• Multiple biopsies with expert review (CHLA, Mayo Clinic, St. Jude consultation)
• Immunohistochemistry (IHC) profiling to characterize the tumor cells
• Molecular testing including OncoKids panel and RNA-Seq gene fusions

✅ Genomic Testing

• Exome Sequencing (WES) - germline analysis
• Whole Genome Sequencing (WGS) - for structural variants
• Liquid biopsy testing (xF+ liquid biopsy)

✅ Advanced Profiling

• BostonGene analysis (tumor microenvironment and immune profiling)
• Organoid development and drug screening (TRACER, SAGE Medic, Certis Oncology)
• PDX (patient-derived xenograft) model development

Potential Gaps Based on NCCN Guidelines

According to the NCCN Guidelines for Soft Tissue Sarcoma, here are areas to consider:

1. Comprehensive Pathologic Grading & Staging Details

The NCCN emphasizes that pathology reports should include:

• Mitotic rate per 10 high-power fields (HPFs) - critical for grade determination
• Presence/absence of vascular invasion - prognostic factor
• Tumor margin characterization (well-circumscribed vs. infiltrative)
• Necrosis assessment - extent and type
• TNM staging - tumor size, nodal involvement, metastatic status

Question for your team: Does Marlo's pathology report explicitly document all these features? Some may be implied but should be clearly stated.

2. Molecular Testing Completeness

NCCN recommends that molecular testing should:

• Use expert pathology review of molecular findings (you have this with Mayo/St. Jude)
• Consider NGS (next-generation sequencing) for actionable mutations - especially important for identifying:
  • Fusion genes (if present)
  • Point mutations in genes like TP53, ATRX, RB1, PTEN
  • Amplifications that might suggest targeted therapy options

Your status: You have WES and WGS, which is excellent. The question is whether these have been analyzed for all clinically actionable variants beyond the initial OncoKids panel.

3. Ancillary Immunohistochemistry for Diagnostic Confirmation

NCCN notes that for spindle cell tumors, IHC should help differentiate from mimics:

• Smooth muscle markers (desmin, SMA, caldesmon)
• Other markers to exclude other diagnoses

Your status: Mayo's report shows negative desmin, myogenin, MYOD-1, which helps confirm this isn't rhabdomyosarcoma. Good.

4. Tumor Microenvironment & Immune Characterization

This is increasingly important for treatment planning:

• Type and extent of inflammatory infiltrate
• Immune cell composition (T cells, macrophages, etc.)
• PD-L1 expression status (relevant for immunotherapy decisions)

Your status: BostonGene analysis should cover this. Confirm that PD-L1 status has been assessed.

5. Imaging Staging

NCCN requires:

• Chest CT with contrast (to rule out lung metastases)
• MRI of primary site (for surgical planning)
• Consider FDG-PET/CT for high-grade or advanced disease

Question for your team: Has complete staging imaging been done? This determines whether Marlo has localized or metastatic disease, which fundamentally changes treatment approach.

---

Critical Questions to Ask Your Oncology Team

Based on NCCN Guidelines and your documents:

1. "Has Marlo's tumor been formally graded (low-grade vs. high-grade) using the FNCLCC or WHO grading system? What is the mitotic rate and necrosis percentage?"

   • Why: Grade determines prognosis and treatment intensity

2. "Are there any actionable mutations identified in the WES/WGS results that might guide targeted therapy selection?"

   • Why: NCCN emphasizes that molecular findings should inform treatment decisions

3. "What is Marlo's complete TNM stage, and has metastatic disease been ruled out with chest imaging?"

   • Why: Staging determines whether this is localized or advanced disease

4. "Has PD-L1 expression been tested, and what is the immune cell composition of the tumor microenvironment?"

   • Why: This informs immunotherapy eligibility and sequencing

5. "Are there any fusion genes or characteristic translocations identified? If not, does the negative result mean they were specifically looked for?"

   • Why: Some spindle cell sarcomas have specific fusions that guide diagnosis and treatment

6. "Given the organoid and PDX models being developed, what is the timeline for drug sensitivity testing results, and which drugs/combinations will be prioritized?"

   • Why: This personalized testing could identify optimal therapy before starting treatment

---

What Your Team Is Doing Well

Your "Treatment & Research Strategy" document shows sophisticated thinking:

✅ Multi-modal approach - combining conventional therapy with precision medicine ✅ Tissue banking - organoid/PDX development for personalized drug testing ✅ Expert consultation - Mayo, St. Jude, Cleveland Clinic pathology review ✅ Emerging therapies - considering FAP-targeted radioligand therapy, CAR-T, peptide vaccines ✅ Comprehensive profiling - BostonGene, genomic sequencing, immune analysis

---

Summary: What Might Be Missing

The main gaps aren't in testing volume but in clarity and completeness:

1. Explicit documentation of all NCCN-required pathologic features (grade, margins, necrosis, vascular invasion)
2. Clear interpretation of which genomic findings are actionable vs. incidental
3. Complete staging with imaging to establish baseline disease extent
4. Immune profiling results (PD-L1, immune cell composition) explicitly documented
5. Timeline for organoid/PDX drug screening - when will results be available to guide treatment decisions?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

---

Sources cited:

• NCCN Guidelines for Soft Tissue Sarcoma (Version 1.2025) - Principles of Pathologic Assessment and Molecular Diagnosis
• Your uploaded [ID removed] and treatment strategy documents

Would you like me to help you formulate specific questions for any of these areas, or explain any of the pathology findings in more detail?